Compare TYRA & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | VVX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2021 | 2014 |
| Metric | TYRA | VVX |
|---|---|---|
| Price | $30.63 | $83.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 8 |
| Target Price | $47.50 | ★ $69.88 |
| AVG Volume (30 Days) | ★ 725.7K | 481.1K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 126.85 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $4,480,038,000.00 |
| Revenue This Year | N/A | $7.81 |
| Revenue Next Year | N/A | $5.84 |
| P/E Ratio | ★ N/A | $139.97 |
| Revenue Growth | N/A | ★ 3.65 |
| 52 Week Low | $9.96 | $46.27 |
| 52 Week High | $40.65 | $91.80 |
| Indicator | TYRA | VVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 64.77 |
| Support Level | $29.68 | $66.71 |
| Resistance Level | $30.70 | $91.80 |
| Average True Range (ATR) | 1.71 | 2.65 |
| MACD | -0.21 | 1.11 |
| Stochastic Oscillator | 16.17 | 85.05 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.